RP-HPLC-PDA Method for the Determination of Paracetamol, Famotidine, Diclofenac Potassium and Chlorzoxazone in Bulk and Marketed Formulation

Abstract

A simple, specific and accurate RP-HPLC-PDA method was developed for the simultaneous determination of paracetamol, famotidine, diclofenac potassium and chlorzoxazone in bulk and marketed formulation. For present study, a reversed-phase Altima C-18 column (150 mm * 4.5 mm i.d., particle size 5 μ) with mobile phase consisting of acetonitrile and 20 mM phosphate buffer (pH of buffer 6.6 adjusted with ortho phosphoric acid) taken in a gradient program was used. The flow rate was maintained at 1.0 ml/min and the analytes were monitored at 270 nm. The mean retention times of paracetamol, famotidine, diclofenac potassium and chlorzoxazone were found to be 4.8, 6.6, 7.7 and 8.8 min, respectively. The method was validated following ICH guidelines including parameters like linearity, range, specificity, system suitability, accuracy, precision and robustness. The proposed method was successfully applied for the estimation of paracetamol, famotidine, diclofenac potassium and chlorzoxazone in combined tablet dosage form.